US 12,215,159 B2
Anti-CD161 antibodies and uses thereof
Alison Tisdale, Belmont, MA (US); Uli Bialucha, Winchester, MA (US); George Punkosdy, Belmont, MA (US); Alexandria Fusco, Derry, NH (US); Frano Irvine, Medford, MA (US); Emily Rosentrater, Marlborough, MA (US); Elizabeth Scanlon, Allston, MA (US); and Michael Battles, Lebanon, NH (US)
Assigned to IMMUNITAS THERAPEUTICS, INC., Waltham, MA (US)
Filed by Immunitas Therapeutics, Inc., Waltham, MA (US)
Filed on Feb. 21, 2024, as Appl. No. 18/582,950.
Application 18/582,950 is a continuation of application No. PCT/US2022/075370, filed on Aug. 23, 2022.
Claims priority of provisional application 63/236,122, filed on Aug. 23, 2021.
Prior Publication US 2024/0279346 A1, Aug. 22, 2024
Int. Cl. C07K 16/00 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2851 (2013.01) [A61P 35/00 (2018.01); A61P 37/04 (2018.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/52 (2013.01)] 30 Claims
 
1. An isolated anti-CD161 antibody comprising:
a heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 sequences, wherein:
(a) the amino acid sequence of CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO: 72;
(b) the amino acid sequence of CDR-H2 comprises the amino acid sequence set forth in SEQ ID NO: 73;
(c) the amino acid sequence of CDR-H3 comprises the amino acid sequence set forth in SEQ ID NO: 74; and
a light chain variable region comprising CDR-L1, CDR-L2 and CDR-L3 sequences, wherein:
(d) the amino acid sequence of CDR-L1 comprises the amino acid sequence set forth in SEQ ID NO: 76;
(e) the amino acid sequence of CDR-L2 comprises the amino acid sequence set forth in SEQ ID NO: 77; and
(f) the amino acid sequence of CDR-L3 comprises the amino acid sequence set forth in SEQ ID NO: 78.